The Clinical Value of Large Neuroimaging Data Sets in Alzheimer's Disease

Neuroimaging Clinics of North America

Volumn 22, Issue 1, 2012, Pages 107-118

  Toga, Arthur W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Database; Informatics; Neuroimaging

Indexed keywords

BIOLOGICAL MARKER;

ACCESS TO INFORMATION; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; BRAIN MAPPING; BRAIN SIZE; COMPUTER SECURITY; FACTUAL DATABASE; GENE; GENETIC ASSOCIATION; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; INFORMATION RETRIEVAL; INTERDISCIPLINARY RESEARCH; MEDICAL INFORMATICS; MORPHOMETRICS; NEUROIMAGING; ONLINE SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REFERENCE DATABASE; REVIEW; THREE DIMENSIONAL IMAGING;

ALZHEIMER DISEASE; DATA MINING; DATABASES, FACTUAL; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; NEUROIMAGING; RADIOLOGY INFORMATION SYSTEMS; USER-COMPUTER INTERFACE;

EID: 84856295588     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2011.11.008     Document Type: Review

References (64)

1. Evans A.C. Large-scale morphometric analysis of neuroanatomy and neuropathology. Anat Embryol 2005, 210(5-6):439-446.
2. Frisoni G.B., Redolfi A., Manset D., et al. Virtual imaging laboratories for marker discovery in neurodegenerative diseases. Nat Rev Neurol 2011, 7(8):429-438.
3. Toga A.W. Guest editorial: a vision of computational anatomy. Biomed Comput Rev 2009, 5(3):1.
4. Joshi S.H., Horn J.D., Toga A.W. Interactive exploration of neuroanatomical meta-spaces. Front Neuroinform 2009, 3:38.
5. Dinov I., Lozev K., Petrosyan P., et al. Neuroimaging study designs, computational analyses and data provenance using the LONI pipeline. PloS One 2010, 5(9). :pii:e13070.
6. Dinov I.D., Van Horn J.D., Lozev K.M., et al. Efficient, distributed and interactive neuroimaging data analysis using the LONI Pipeline. Front Neuroinform 2009, 3:22.
7. Shattuck D.W., Prasad G., Mirza M., et al. Online resource for validation of brain segmentation methods. Neuroimage 2009, 45(2):431-439.
8. Shi Y., Lai R., Morra J.H., et al. Robust surface reconstruction via Laplace-Beltrami eigen-projection and boundary deformation. IEEE Trans Med Imaging 2010, 29(12):2009-2022.
9. Cohen J.R., Asarnow R.F., Sabb F.W., et al. Decoding continuous variables from neuroimaging data: basic and clinical applications. Front Neurosci 2011, 5:75.
10. Pievani M., de Haan W., Wu T., et al. Functional network disruption in the degenerative dementias. Lancet Neurol 2011, 10(9):829-843.
11. Toga A.W., Thompson P.M., Mori S., et al. Towards multimodal atlases of the human brain. Nat Rev Neurol 2006, 7(12):952-966.
12. Van Horn J.D., Toga A.W. Multisite neuroimaging trials. Curr Opin Neurol 2009, 22(4):370-378.
13. Sporns O. The human connectome: a complex network. Ann N Y Acad Sci 2011, 1224(1):109-125.
14. Biswal B.B., Mennes M., Zuo X.N., et al. Toward discovery science of human brain function. Proc Natl Acad Sci U S A 2010, 107(10):4734-4739.
15. Mackenzie-Graham A.J., Van Horn J.D., Woods R.P., et al. Provenance in neuroimaging. Neuroimage 2008, 42(1):178-195.
16. Toga A.W., Thompson P.M. What is where and why it is important. Neuroimage 2007, 37(4):1045-1049. [discussion: 1066-8].
17. Zhang D., Wang Y., Zhou L., et al. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011, 55(3):856-867.
18. Ewers M., Frisoni G.B., Teipel S.J., et al. Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol 2011, 95(4):535-546.
19. Hua X., Leow A.D., Lee S., et al. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage 2008, 41(1):19-34.
20. Leow A.D., Yanovsky I., Parikshak N., et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45(3):645-655.
21. Madsen S.K., Ho A.J., Hua X., et al. 3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects. Neurobiol Aging 2010, 31(8):1312-1325.
22. Thompson P.M., Hayashi K.M., Dutton R.A., et al. Tracking Alzheimer's disease. Ann N Y Acad Sci 2007, 1097:183-214.
23. Morra J.H., Tu Z., Apostolova L.G., et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp 2009, 30(9):2766-2788.
24. Westman E., Simmons A., Muehlboeck J.S., et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011, 58(3):818-828.
25. Sakoglu Ü, Upadhyay J., Chin C.L., et al. Paradigm shift in translational neuroimaging of CNS disorders. Biochem Pharmacol 2011, 81(12):1374-1387.
26. Schumann G., Loth E., Banaschewski T., et al. The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry 2010, 15(12):1128-1139.
27. Aisen P.S., Petersen R.C., Donohue M.C., et al. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement 2010, 6(3):239-246.
28. Beckett L.A., Harvey D.J., Gamst A., et al. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement 2010, 6(3):257-264.
29. Petersen R.C., Aisen P.S., Beckett L.A., et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology 2010, 74(3):201-209.
30. Toga A.W., Crawford K.L. The informatics core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 2010, 6(3):247-256.
31. Weiner M.W., Aisen P.S., Jack C.R., et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010, 6(3):202-211.
32. Thal L.J., Kantarci K., Reiman E.M., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(1):6-15.
33. Cavedo E., Frisoni G.B. The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging. QJ Nucl Med Mol Imaging 2011, 55(3):237-249.
34. Jagust W.J., Bandy D., Chen K., et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010, 6(3):221-229.
35. Kohannim O., Hua X., Hibar D.P., et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 2010, 31(8):1429-1442.
36. Petersen R.C. Alzheimer's disease: progress in prediction. Lancet Neurol 2010, 9(1):4-5.
37. Jack C.R., Knopman D.S., Jagust W.J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
38. Jack C.R., Wiste H.J., Vemuri P., et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133(11):3336-3348.
39. Hampel H., Shen Y., Walsh D.M., et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010, 223(2):334-346.
40. Hampel H., Wilcock G., Andrieu S., et al. Biomarkers for Alzheimer's diseasetherapeutic trials. Prog Neurobiol 2010, 95(4):579-593.
41. Holland D., Brewer J.B., Hagler D.J., et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106(49):20954-20959.
42. Apostolova L.G., Steiner C.A., Akopyan G.G., et al. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol 2007, 64(10):1489-1495.
43. Apostolova L.G., Thompson P.M., Green A.E., et al. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010, 31(5):786-797.
44. Risacher S.L., Saykin A.J., West J.D., et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009, 6(4):347-361.
45. Fennema-Notestine C., Hagler D.J., McEvoy L.K., et al. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp 2009, 30(10):3238-3253.
46. Karow D.S., McEvoy L.K., Fennema-Notestine C., et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 2010, 256(3):932-942.
47. Leung K.K., Barnes J., Ridgway G.R., et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 2010, 51(4):1345-1359.
48. McDonald C.R., McEvoy L.K., Gharapetian L., et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009, 73(6):457-465.
49. Hua X., Leow A.D., Parikshak N., et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 2008, 43(3):458-469.
50. Schuff N., Tosun D., Insel P.S., et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging 2010, [Epub ahead of print].
51. McEvoy L.K., Fennema-Notestine C., Roddey J.C., et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009, 251(1):195-205.
52. Qiu A., Fennema-Notestine C., Dale A.M., et al. Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroimage 2009, 45(3):656-661.
53. Apostolova L.G., Morra J.H., Green A.E., et al. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage 2010, 51(1):488-499.
54. Morra J.H., Tu Z., Apostolova L.G., et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage 2008, 43(1):59-68.
55. Morra J.H., Tu Z., Apostolova L.G., et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009, 45(Suppl 1):S3-15.
56. Wolz R., Heckemann R.A., Aljabar P., et al. Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage 2010, 52(1):109-118.
57. Risacher S.L., Shen L., West J.D., et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010, 31(8):1401-1418.
58. Vemuri P., Wiste H.J., Weigand S.D., et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010, 67(3):308-316.
59. Hua X., Hibar D.P., Lee S., et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging 2010, 31(8):1463-1480.
60. Ho A.J., Raji C.A., Becker J.T., et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging 2010, 31(8):1326-1339.
61. Wu X., Chen K., Yao L., et al. Assessing the reliability todetect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. JNeurosci Methods 2010, 192(2):277-285.
62. Chen K., Langbaum J.B., Fleisher A.S., et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 2010, 51(2):654-664.
63. Ewers M., Sperling R.A., Klunk W.E., et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011, 34(8):430-442.
64. Valenzuela M., Bartrés-Faz D., Beg F., et al. Neuroimaging as endpoints in clinical trials: are we there yet? Perspective from the first Provence workshop. Mol Psychiatry 2011, 16(11):1064-1066.